Formulation and Characterization of Nanoparticles Loaded with Cefadroxil

 

Hemalatha.C. N*, Yeswanth Prasanna Kumar. B, Vijey Anandhi. M

School of Pharmaceutical Sciences, Vels University, Chennai, Tamilnadu, India

*Corresponding Author E-mail: hodpchemistry@velsuniv.ac.in

 

ABSTRACT:

Nanotechnology encompass a range of techniques rather than a single discipline and stretches across the whole spectrum of science, touching medicines, physics, engineering and chemistry. Targeted delivery of ingredients to a particular cell type or receptor. Capable of heat triggered local release. Nanoparticles are made up of non-biodegradable polymers such as methylmethacrylate or it can also be made from biodegradable polymers such as alkylcyano acrylate and albumin.  Numerous methods exist for the manufacture of preparation of nanoparticles, allowing extensive modulation of their structure, composition and physiochemical properties. Formulation of nanoparticles of Cefadroxil using Albumin and Eudragit RL 100 in the ratios 1:1 and 1:2. Characterization of nanoparticles and invitro release of drugs has been carried out. In vitro release studies of each polymer was evaluated the synthetic polymer was exhibiting more extended release than natural polymer and the proportion have its influence in extending the release rate of the drug. The half-life of drug using Albumin loaded is 4hr and using Eudragit RL 100 is 4-5hr. Anti-bacterial studies has been done to confirm the anti-bacterial activity.

 

KEYWORDS: Nanoparticles, Albumin, Eudragit RL 100, antibacterial.

 

 


INTRODUCTION:

Nanotechnology is the science of the extremely tiny. It involves the study and use of materials on an unimaginably small scale. Nano refers to a nanometre (nm). (1)One nanometre millionth of a millimetre or about one eighty thousandth the width of a human hair. Nanotechnology encompass a range of techniques rather than a single discipline and stretches across the whole spectrum of science, touching medicines, physics, engineering and chemistry.

 

Nanotechnology in Medicines:

Nanotechnology involve the identification of precise targets (cells and receptors) related to specific clinical conditions and choice of the appropriate Nano carriers to achieve the required responses while minimizing the side effects.(2)

 

Nanoparticles:

Nanoparticles consists of macromolecular materials and can be used therapeutically for e.g. as adjuvant in vaccines or drug carriers in which the active principle (drug or bioavailability active material) is dissolved, entrapped or encapsulated and which the active principle is absorbed or attached.

 

Carriers Used in The Preparation of Nanoparticles:

The polymers used for the preparation of nanoparticles are either Amphiphilic macromolecules, obtained from natural sources, hydrophilic polymers or synthesized chemically.(3)

 

Characterization:

 

Physiological methods for the characterization of nanoparticles are listed. Size is their most prominent feature, although other parameters, such as density, molecular weight, and crystallinity, influence nanoparticles release and degeneration properties, whereas surface charge, hydrophilicity and hydrophobicity significantly influence the interaction with the biological environment after administration to humans and animals and the resulting body distribution.(4,5,6)

 

INTRODUCTION ABOUT THE DRUG

 

These are a group of semi-synthetic antibiotic derived from “Cephalosporin –C” obtained from fingers “Cephalosporin”. They are chemically related to penicillin.  Cefadroxil is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positiveand  Gram-negative bacterial infections. It is a bactericidal antibiotic.

 

HALF LIFE: About 1-4 hour to 2-6 hour.

 

POLYMER PROFILE EUDRAGIT RL 100:

EUDRAGIT RL 100 is a copolymer of ethyl acrylate, methyl methacrylate and a low content of methacrylic acid ester with quaternary ammonium groups. The ammonium groups are present as salts and make the polymers permeable. Physical properties: It is a solid substance in form of colourless, clear to cloudy granules with a faint amine-like odour.

 

SOLUBILITY:

Table - 1

Type

AA

DCM

SEA

1N HCl

1N NaOH

PE

W

Eudragit RL 100

S

S

S

-

-

I

I

Where, AA= Acetone and Alcohols ; DCM= Di-chloromethane; SEA=Solvent Ethyl acetate; PE= Petroleum ether; W= Water; S= soluble; I= Insoluble or immiscible ; Alcohols including ethanol, methanol and propane 2 – ol.

 

MATERIALS AND METHODS:

Preparation of Cefadroxil Loaded Egg Albumin and Eudragit Nanoparticles:

Drug polymer ratio

Drug      :              polymer

1             :              1

1             :              2

 

Table - 2

S.No

Egg albumin nanoparticles

Eudragitnano particles

1

Cefadroxil

Cefadroxil

2

Albumin

Eudragit RL-100

3

10% HCl

Chloroform

4

5% NaOH

Gelatin

5

Acetone

Cooling centrifuge

6

4% Gluteraldehyde

Ultra Sonicator

7

Electronic single pan balance

Electronic single pan balance

8

pH meter

Vacuum drier

9

U.V. Visible Spectrophotometer

 

10

Centrifuge

 

11

Vacuum Drier

 

12

Ultra Sonicator

 

 

 

Procedure of egg albumin nanoparticles:

Nanoparticles were prepared by pH – coaservation method. 100mg of egg albumin was taken in 50ml beaker and mixed with 100mg of the drug solution in 10% HCl then adjusted the pH to 8. The solution was sonicated by Ultra Sonicator with 5% NaOH solution and acetone was added drop wise from a syringe until the solution become turbid. The formed particles are cross linked by adding 100ml of 4% gluteraldehyde solution was sonicated continuously for 3 hours at room temperature.(7,8) After the cross linking stage, the egg albumin nanoparticles were centrifuged at 5000rpm for 30 minutes. After centrifuging the supernatant liquid was removed and the suspension was washed till it is free from acetone and then finally dried in a vacuum drier.(9)

 

Procedure of eudragit nanoparticles:

The drug Cefadroxil polymer Eudragit are accurately weighed and Cefadroxil was dissolved in water and Eudragit in chloroform. The two solutions are mixed and were emulsified by ultrasonification for 45 minutes at 15°C in an aqueous 0.5% W/W Gelatin solution.(9) The solvent evaporate during 45 minutes at 40°C under continuous sonification. The nanoparticles formed is separated by Fractional centrifugation using a cooling centrifuge. The solution was centrifuged for about 15,000 rpm at 20°C for 15 minute. The supernatant fluid was discarded. The product was dried in vacuum drier.

 

Standard curve of Cefadroxil has been estimated. Dissolution study has been carried out.

 

Fig. 2: Standard curve for pure drug (CEFADROXIL)

Characterization

Drug Content Analysis:

The drug content for Albumin loaded nanoparticles was analysed by adding 100ml of 1% hydrochloric acid solution with 0.1 ml of formulated nanoparticle and kept at room temperature for 24 hrs. (10, 11,12, 13)

 

Drug loaded capacity =

 

mg of drug bound by total amount of nanoparticles

          Total amount of applied drug (mg)

 

The method adopted to carry out the invitro antibacterial activity was filter paper disc and media used was Muehler Hinton Agar.

 

RESULTS AND DISCUSSIONS:

Shorter biological half-life may necessities. Repeated administration of drug, which may reduce patient convenience and compliance Cephalosporin group of antibiotics, cefadroxil exhibits a shorter biological half-life, with wide anti-bacterial activity which required frequent doses, in order to reduce the toxicity and frequency Cefadroxil nanoparticle was formulated. Nanoparticle carrier of Cefadroxil was formulated using a natural polymer Albumin and a synthetic polymer Eudragit in the ratio 1:1 and 1:2. Two methods were adopted for the formulation one method adopted was the cross-linking method by using Eudragit polymer and the other being the pH-coacervation method using albumin as carrier drug polymer ratio and the cross link was presented.

 

Table – 3 Synthetic and Drug Polymer Ratio

S.NO

Batch Code

Amount of drug

Amount of polymer

Conc of cross-links agent

Drug-polymer ratio

1

A1

100mg

100mg

4% Gluteraldehyde

1:1

2

A2

200mg

200mg

4% Gluteraldehyde

1:2

3

E1

100mg

100mg

0.5% w/w Gelatin

1:1

4

E2

200mg

200mg

0.5% w/w Gelatin

1:2

A1 = 1:1; E1 = 1:1;   A2 = 1:2; E2 = 1:2 

 

Table – 4 Absorbance and Concentration

S.No

Formulations

Absorbance

Concentration %

1

A1

0.96

50.52%

2

A2

0.89

46.84%

3

E1

0.90

47.37%

4

E2

0.93

48.94%

A1 = 1:1    ; E1 = 1:1;  A2 = 1:2; E2 = 1:2 


 

 

Table – 5 Drug release rate of pure drug (CEFADROXIL)

Time

in hrs

Absorbance

Conc

mg/ml

Conc mg/900ml

% Release

30 min

0.5428

28.57

25.72

25.72

1hr

0.7486

39.4

35.46

35.46

2hr

1.1315

59.55

53.6

53.6

3hr

1.5276

80.4

72.36

72.36

4hr

1.9025

100.13

90.12

90.12

 

Table – 6 Drug release rate of ALBUMIN loaded Nano particles (Ratio 1:1)

Time

in hrs

Absorbance

Conc mg/ml

Conc mg/900 ml

% Release

1hr

0.6126

32.24

29.02

29.02

2hr

0.788

41.47

37.33

37.33

3hr

0.9611

50.59

45.53

45.53

4hr

1.1136

58.61

52.75

52.75

5hr

1.3874

73.02

65.72

65.72

6hr

1.5436

81.24

73.12

73.12

7hr

1.7955

94.5

85.05

85.05

 

 

Table – 7 Drug release rate of ALBUMIN loaded Nano particles (Ratio 1:2)

Time in hrs

Absorbance

Conc mg/ml

Conc mg/900 ml

% Release

1hr

0.488

25.69

23.12

23.12

2hr

0.6232

33.06

29.76

29.76

3hr

0.8148

42.88

38.6

38.6

4hr

1.001

52.68

47.42

47.42

5hr

1.273

67

60.3

60.3

6hr

1.4197

74.72

67.25

67.25

7hr

1.6747

88.14

79.33

79.33

8hr

1.8698

98.41

88.57

88.57

 

 

Table – 8 Drug release rate of EUDRAGIT loaded Nano particles (Ratio 1:1)

Time in hrs

Absorbance

Conc mg/ml

Conc mg/900 ml

% Release

1hr

0.3614

19.02

17.12

17.12

2hr

0.4678

24.62

22.16

22.16

3hr

0.5979

31.46

28.32

28.32

4hr

0.7653

40.28

36.25

36.25

5hr

0.9204

48.44

43.6

43.6

6hr

1.1214

59.02

53.12

53.12

7hr

1.2947

68.14

61.33

61.33

8hr

1.4682

77.28

69.55

69.55

9hr

1.6331

85.96

77.36

77.36

 

 

 

Table – 9 Drug release rate of EUDRAGIT loaded Nano particles (Ratio 1:2)

Time in hrs

Absorbance

Conc mg/ml

Conc mg/900 ml

% Release

1hr

0.2603

13.7

12.33

12.33

2hr

0.3884

20.44

18.4

18.4

3hr

0.487

25.63

23.07

23.07

4hr

0.6365

33.5

30.15

30.15

5hr

0.7963

41.91

37.72

37.72

6hr

0.9578

50.41

45.37

45.37

7hr

1.1159

58.73

52.86

52.86

8hr

1.278

67.27

60.54

60.54

9hr

1.4836

78.07

70.26

70.26

 

Fig. 3 Comparison and release rate of pure drug and formulated nanoparticles

 

Comparison and release rate of pure drug and formulated nanoparticles

Table – 10

Name of strain

Zone of inhibition in nm

Bacterial strain

Standard

A1

A2

E1

E2

Klebsiella

19

16

14

11

10

Streptococcus

20

11

15

12

13

Staphylococcus

22

17

12

18

11

 

In vitro antibacterial studies was done to confirm the efficacy of the formulation by measuring the zone of inhibition and the result were presented in table X.

 

Anti bacterial activity of formulated nono particles

 

 

SUMMARY AND CONCLUSION:

Cefadroxil an antibacterial drug was loaded in Nano particulate carrier using albumin and polymethacrylate polymers in different ratios by cross linking method and pH-coacervation method. Time, speed of sonication and temperature were standardized to yield good formulation.  Drug content and loading analysis confirms the entrapment of drug in the carrier. In vitro release studies of each polymer was evaluated the synthetic polymer was exhibiting more extended release than natural polymer and the proportion have its influence in extending the release rate of the drug. Invitro anti-bacterial studies confirms the efficacy of the antibacterial agent in the formulations, which was done by measuring zone of inhibition. Above studies reveals that the antibacterial activity of cefadroxil can be maintained and extended over a period of time, reducing the frequency of doses.

 

REFERENCE:

1.       Aliautdin, R. N., V. E. Petrov, et al. (1998). "[The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles]." Eksp Klin Farmakol 61(1): 17-20.

2.       Allemann, E., J. C. Leroux, et al. (1993). "In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure." Pharmacetical Research 10(12): 1732-7.

3.       Coester, C. J., K. Langer, et al. (2000). "Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake." Journal of Microencapsulation 17(2): 187-93.

4.       Couvreur, P., E. Fattal, et al. (1991). "Liposomes and nanoparticles in the treatment of intracellular bacterial infections."Pharm Res 8(9): 1079-86.

5.       Fontana, G., G. Pitarresi, et al. (1998). "Preparation, characterization and in vitro antimicrobial activity of ampicillin-loaded polyethylcyanoacrylate nanoparticles." Biomaterials 19(11-12): 1009-17.

6.       Fresta, M., G. Cavallaro, et al. (1996). "Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs." Biomaterials 17(8): 751-8.

7.       Guise, V., J. Y. Drouin, et al. (1990). "Vidarabine-loaded nanoparticles:aphysicochemical study." Pharm Res 7(7): 736- 41.

8.       Gulyaev, A. E., S. E. Gelperina, et al. (1999). "Significant transport of doxorubicin into the brain with polysorbate 80- coated nanoparticles." Pharm Res 16(10): 1564-9.

9.       Guzman, M., J. Molpeceres, et al. (1993). "Formation and characterization of cyclosporine-loaded nanoparticles." Journal of Pharmaceutical Sciences 82(5): 498-502.

10.     Kreuter, J. (1991). "Liposomes and nanoparticles as vehicles for antibiotics." Infection 19(Suppl 4(1)): S224-8.

11.     Kreuter, J. (1994). "Drug targeting with nanoparticles." European Journal of Drug Metabolism and Pharmacokinetics 19(3): 253-6.

12.     Kreuter, J., R. N. Alyautdin, et al. (1995). "Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)." Brain Research 674(1): 171-4.

13.     Lin, W., M. C. Garnett, et al. (2001). "Preparation and characterisation of rose Bengal-loaded surface-modified albuminnanoparticles." Journal of Control Release 71(1): 117-26.

 

 

 

 

Received on 29.08.2016          Modified on 30.09.2016

Accepted on 01.11.2016        © RJPT All right reserved

Research J. Pharm. and Tech. 2017; 10(1): 183-187.

DOI: 10.5958/0974-360X.2017.00040.3